Vericel (NASDAQ:VCEL – Get Free Report) and Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.
Profitability
This table compares Vericel and Avalo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 10.27% | 9.09% | 6.68% |
| Avalo Therapeutics | N/A | -34.21% | -29.84% |
Risk and Volatility
Vericel has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Earnings & Valuation
This table compares Vericel and Avalo Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $276.26 million | 10.52 | $16.52 million | $0.64 | 89.00 |
| Avalo Therapeutics | $60,000.00 | 7,478.05 | -$78.26 million | ($2.52) | -3.08 |
Vericel has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
87.1% of Avalo Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations for Vericel and Avalo Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 0 | 1 | 5 | 1 | 3.00 |
| Avalo Therapeutics | 1 | 2 | 11 | 0 | 2.71 |
Vericel currently has a consensus target price of $62.00, indicating a potential upside of 8.85%. Avalo Therapeutics has a consensus target price of $36.82, indicating a potential upside of 374.46%. Given Avalo Therapeutics’ higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than Vericel.
Summary
Vericel beats Avalo Therapeutics on 11 of the 15 factors compared between the two stocks.
About Vericel
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
